Table 4. Antimicrobial susceptibility and MDR among 294 Salmonella enterica isolates obtained from humans with infections in Guangdong province, China, between 2007 and 2011.
No. ofisolates | ampicillin | ceftazidime | cefotaxime | cefepime | ciprofloxacin | nalidixicacid | Sulfamethoxazole | trimethoprim | tetracycline | gentamicin | streptomycin | chloramphenicol | MDR | |
ST34 | 209 | 202(96.65) | 21(10.05) | 28(13.39) | 25(11.97) | 12(5.74) | 197(94.26) | 204 (98.06) | 163(77.99) | 202(96.65) | 157(75.12) | 172(82.30) | 178 (85.17) | 206 (98.56) |
ST19 | 69 | 44(63.77) | 2(2.89) | 6(8.69) | 4(5.79) | 10(14.49) | 36(52.17) | 46 (66.67) | 37(53.62) | 46(66.66) | 28(40.58) | 47(68.12) | 31(30.55) | 49(71.01) |
ST36 | 5 | 3(60.00) | 1 (20.00) | 2 (40.00) | 0 | 1 (20.00) | 2(40.00) | 4 (80.00) | 2(40.00) | 4(80.00) | 1(20.00) | 4(80.00) | 3(60.00) | 4 (80.00) |
ST1776 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
ST1777 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ST1778 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
ST1779 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
ST1780 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
ST1781 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
ST1782 | 2 | 2 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 1 |
ST1785 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 |
ST1790 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
ST1791 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 |
Total(% resistance)b | 294 | 258(87.75) | 25(8.50) | 38(12.93) | 32(10.88) | 24(8.16) | 243(82.65) | 264(89.79) | 210(71.43) | 262(89.12) | 192(65.31) | 231(78.57) | 219(74.49) | 268(91.16) |
Number of isolates resistant to indicated agent at the indicated breakpoint (% resistance)a.
The percentage means the proportion of resistant isolates for each antibiotics.
The percentage means the proportion of MDR isolates among the total isolates.